TherapeuticsMD Inc (NASDAQ:TXMD) Stake Raised by Moloney Securities Asset Management LLC
Moloney Securities Asset Management LLC grew its holdings in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 42.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company’s stock after buying an additional 4,500 shares during the period. Moloney Securities Asset Management LLC’s holdings in TherapeuticsMD were worth $54,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of TherapeuticsMD by 3.7% during the second quarter. BlackRock Inc. now owns 15,991,138 shares of the company’s stock valued at $41,577,000 after buying an additional 576,601 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of TherapeuticsMD by 5.7% during the second quarter. Vanguard Group Inc. now owns 14,562,689 shares of the company’s stock valued at $37,862,000 after buying an additional 788,467 shares during the last quarter. Bamco Inc. NY raised its holdings in TherapeuticsMD by 41.8% during the second quarter. Bamco Inc. NY now owns 3,331,500 shares of the company’s stock worth $8,662,000 after purchasing an additional 981,500 shares in the last quarter. AXA raised its holdings in TherapeuticsMD by 15.2% during the second quarter. AXA now owns 3,212,524 shares of the company’s stock worth $8,353,000 after purchasing an additional 423,770 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its holdings in TherapeuticsMD by 222.3% during the second quarter. C WorldWide Group Holding A S now owns 3,189,834 shares of the company’s stock worth $8,294,000 after purchasing an additional 2,200,000 shares in the last quarter. 78.23% of the stock is currently owned by institutional investors.
In other news, insider John C.K. Iv Milligan acquired 72,000 shares of the stock in a transaction on Friday, October 25th. The shares were purchased at an average cost of $2.75 per share, for a total transaction of $198,000.00. Following the transaction, the insider now owns 1,544,419 shares in the company, valued at approximately $4,247,152.25. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Angus C. Russell acquired 35,000 shares of the stock in a transaction on Thursday, August 15th. The shares were purchased at an average price of $2.83 per share, for a total transaction of $99,050.00. Following the completion of the transaction, the director now owns 73,500 shares in the company, valued at approximately $208,005. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 216,144 shares of company stock worth $606,348. 18.91% of the stock is currently owned by company insiders.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. The firm had revenue of $8.21 million for the quarter, compared to analyst estimates of $8.05 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The firm’s quarterly revenue was up 136.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.16) earnings per share. Equities analysts expect that TherapeuticsMD Inc will post -0.73 earnings per share for the current year.
Several equities research analysts recently commented on the company. BidaskClub cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Tuesday, October 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of TherapeuticsMD in a report on Wednesday, August 7th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, October 19th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of TherapeuticsMD in a report on Tuesday, October 29th. Finally, Stifel Nicolaus dropped their target price on TherapeuticsMD from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, October 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.11.
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Recommended Story: Correction
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.